Lora Hamuro

机构：Bristol-Myers Squibb (Germany), Bristol-Myers Squibb (Sweden), Bristol-Myers Squibb (Belgium) · ORCID：0000-0003-2367-1926

发表论文 87 篇 · 总被引 3636 次 · h-index 27

代表论文

• A Novel and Cost Effective Method of Removing Excess Albumin from Plasma/Serum Samples and Its Impacts on LC-MS/MS Bioanalysis of Therapeutic Proteins (2014 · Analytical Chemistry · 被引 95)
• Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins (2017 · Journal of Pharmaceutical Sciences · 被引 90)
• The effect of the neonatal Fc receptor on human IgG biodistribution in mice (2014 · mAbs · 被引 57)
• Immunogenicity in Clinical Practice and Drug Development: When is it Significant? (2019 · Clinical and Translational Science · 被引 28)
• Nivolumab Clearance Is Stationary in Patients With Resected Melanoma on Adjuvant Therapy: Implications of Disease Status on Time‐Varying Clearance (2019 · Clinical Pharmacology & Therapeutics · 被引 27)
• The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy (2024 · Neurology and Therapy · 被引 26)